- Conditions
- Neoplams
- Interventions
- MRI
- Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- San Francisco, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 649–672
of 2,124
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Select Advanced Solid Tumors
- Interventions
- Cyclophosphamide, Fludarabine, KSQ-004EX, Interleukin-2
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2041
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Merkel Cell Carcinoma, Basal Cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Cancer
- Interventions
- RP1, intra-tumoral injection, oncolytic virus
- Biological
- Lead sponsor
- Replimune, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 20 more
- Conditions
- Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
- Interventions
- MRTX849, TNO155
- Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Orange, California • Chicago, Illinois + 9 more
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- warfarin
- Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer, RAS G12D-mutated NSCLC
- Interventions
- RMC-6291, RMC-6236, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, RMC-9805
- Drug
- Lead sponsor
- Revolution Medicines, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 616 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 29
- States / cities
- Gilbert, Arizona • Duarte, California • Irvine, California + 24 more
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Sapanisertib
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Advanced Solid Tumor, Lymphomas
- Interventions
- LEE011
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Ann Arbor, Michigan • New York, New York + 1 more
- Conditions
- Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Urothelial Cancer
- Interventions
- AVZO-103, Combination Agent
- Drug
- Lead sponsor
- Avenzo Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 355 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 15
- States / cities
- San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 12 more
- Conditions
- Solid Tumors
- Interventions
- IPI-504, docetaxel
- Drug
- Lead sponsor
- Infinity Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • New Haven, Connecticut • Tampa, Florida + 5 more
- Conditions
- Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
- Interventions
- alvespimycin hydrochloride, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Advanced Solid Malignancy, Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, Tumour Response, Advanced or Metastatic Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, PIK3CA, AKT1, PTEN, ER Positive, HER2 Positive
- Interventions
- AZD5363
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2024
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Stanford, California • West Hollywood, California + 8 more
- Conditions
- Solid Tumor
- Interventions
- ixabepilone, Dasatinib
- Drug
- Lead sponsor
- Medstar Health Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Advanced Solid Tumor, Melanoma, Lung Neoplasms, Head and Neck Neoplasms
- Interventions
- KSQ-001EX, Interleukin-2, Cyclophosphamide, Fludarabine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Neoplasms
- Interventions
- Copanlisib (Aliqopa, BAY80-6946)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Pittsburgh, Pennsylvania • San Antonio, Texas
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- NMS-1286937
- Drug
- Lead sponsor
- Nerviano Medical Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Advanced Solid Tumors
- Interventions
- sapacitabine and seliciclib
- Drug
- Lead sponsor
- Cyclacel Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2019
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Solid Tumors
- Interventions
- RO6958688, Obinutuzumab, Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Palo Alto, California • Santa Monica, California + 6 more
- Conditions
- Advanced Solid Tumors, Multiple Myeloma
- Interventions
- ACE-041
- Biological
- Lead sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Durham, North Carolina • Nashville, Tennessee + 1 more
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Solid Tumor, Adult, Solid Tumor, Metastatic Castration-resistant Prostate Cancer
- Interventions
- Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, 11C-YJH08, Optional Tumor Biopsy
- Procedure · Drug
- Lead sponsor
- Rahul Aggarwal
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Solid Tumor
- Interventions
- Hu5F9-G4
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 6
- States / cities
- Stanford, California • Chicago, Illinois • Grand Rapids, Michigan + 3 more
- Conditions
- Carcinoma, Advanced Cancer
- Interventions
- TRX-818 capsules
- Drug
- Lead sponsor
- TaiRx, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 2
- States / cities
- Grand Rapids, Michigan • San Antonio, Texas
- Conditions
- Mesothelioma, Non Small Cell Lung Cancer, Malignant Peripheral Nerve Sheath Tumors, Solid Tumor, Pancreatic Adenocarcinoma, Advanced Solid Tumor
- Interventions
- MRTX1719
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Lone Tree, Colorado • Jacksonville, Florida + 20 more
- Conditions
- Advanced Solid Tumors, Hematologic Malignancies
- Interventions
- IXAZOMIB
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 4
- States / cities
- Fairway, Kansas • Cleveland, Ohio • Dallas, Texas + 1 more